Guide

D-Chiro Inositol + Myo-Inositol: The Proven PCOS Hormone Combination

Updated Apr 26, 2026 · 7 min read
Sensitive populations: This article references pregnancy. Always confirm any supplement change with your obstetrician or midwife before starting — dosing, contraindications, and risk profile shift in these groups.

Inositol is a sugar alcohol with nine stereoisomers. Two of them — myo-inositol (MI) and D-chiro-inositol (DCI) — serve as second messengers for insulin signaling. Women with polycystic ovary syndrome (PCOS) have disrupted tissue ratios of MI to DCI, with ovarian DCI deficiency contributing to hyperandrogenism and ovulatory dysfunction. Correcting this ratio is one of the better-supported nutritional interventions in reproductive endocrinology.

The 40:1 Ratio

Healthy plasma MI:DCI is roughly 40:1. In PCOS, the ratio is distorted due to elevated epimerase activity in ovarian tissue. The Nordio & Proietti 2012 RCT (European Review for Medical and Pharmacological Sciences; PMID 22774396) randomized 50 overweight women with PCOS to MI alone vs MI + DCI for 6 months and showed that the MI + DCI combination outperformed MI alone on metabolic and ovarian outcomes. Subsequent ratio-finding work by the same group and the 2015 Italian consensus recommended a 40:1 MI:DCI ratio (typically 2,000 mg MI + 50 mg DCI twice daily) as the most physiological. Products delivering DCI alone, or only MI, tended to over- or under-correct the imbalance.

Ovulation and Pregnancy Outcomes

The 2017 Unfer meta-analysis in Endocrine Connections (PMID 29042448) pooled 9 RCTs (247 cases, 249 controls) and found significant decreases in fasting insulin and HOMA-IR with MI alone or with DCI, plus a non-significant trend toward lower testosterone. Subsequent meta-analyses (e.g., Pundir et al., BJOG 2018; PMID 28759180) reported improvements in ovulation rate and clinical pregnancy with inositols compared with placebo or metformin in PCOS, with lower side-effect burden than metformin. Metabolic improvements typically appear by 3 months; fertility improvements often need 3–6 months of consistent use.

Beyond PCOS

Myo-inositol at 4 g/day has shown benefit for gestational diabetes prevention in high-risk women, and at 12–18 g/day has shown efficacy comparable to SSRIs for panic disorder in small controlled trials. These higher doses are safe but cause osmotic GI symptoms (loose stools, bloating) in some users.

Practical Notes

Inositol is one of the better-tolerated supplements in the reproductive space, with GI upset being the main side effect at high doses. It can be combined with metformin safely and often works at least as well as metformin alone for ovulatory restoration with fewer side effects. Women planning conception should pair it with adequate folate intake.

Sources

  1. Nordio M, Proietti E. "The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone." European Review for Medical and Pharmacological Sciences, 2012. PMID 22774396.
  2. Unfer V, et al. "Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials." Endocrine Connections, 2017. PMID 29042448.
  3. Pundir J, et al. "Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials." BJOG, 2018. PMID 28759180.
  4. Facchinetti F, et al. "Results from the international consensus conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology." Gynecological Endocrinology, 2019.